Dianthus Therapeutics, Inc. DE (DNTH)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 193 | 1,163 | 2,172 | |
| Research and development | 26,251 | 27,003 | 25,544 | |
| General and administrative | 8,869 | 7,337 | 6,528 | |
| Total operating expenses | 35,120 | 34,340 | 32,072 | |
| Loss from operations | -34,927 | -33,177 | -29,900 | |
| Interest income, other | - | - | 4,445 | |
| Gain on investment in related party | - | - | 307 | |
| Loss on investment in related party | - | 5 | - | |
| Other expense | -107 | -98 | 22 | |
| Interest and investment income | 3,403 | 3,791 | - | |
| Loss on currency exchange, net | -30 | -22 | -48 | |
| Gain on investment in former related party | 32 | - | - | |
| Total other income | 3,298 | 3,666 | 4,726 | |
| Net loss | -31,629 | -29,511 | -25,174 | |
| Unrealized loss on marketable securities | -172 | 164 | 718 | |
| Total other comprehensive loss | -172 | 164 | 718 | |
| Total comprehensive loss | -31,801 | -29,347 | -24,456 | |
| Net loss per share attributable to common stockholders, basic | -0.88 | -0.82 | -0.74 | |
| Net loss per share attributable to common stockholders, diluted | -0.88 | -0.82 | -0.74 | |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic | 35,822,308 | 35,790,700 | 34,236,728 | |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, diluted | 35,822,308 | 35,790,700 | 34,236,728 | |